Abstract
Gene therapy, developing rapidly as a result of advances in molecular biology and the Human Genome Project, is now highlighted as a most hopeful technology of the 21st century. The major goal of gene therapy in diabetes mellitus (DM) is to maintain euglycemia in face of wide variations in dietary intake. Although some obstacles remain to be overcome, the risk-benefit ratio of gene therapy in DM is better than that of lifelong injections of insulin, and islet transplantation, which faces the problems of donor shortage and rejection. This review focuses on the recent advances in gene therapy of insulin-requiring diabetes, with particular emphasis on 1. the gene delivery systems by viral vectors, since most gene therapy approaches for DM involve the use of viral vectors, paying special attention to current efforts to overcome the disadvantages of adenovirus, adenovirus-associated virus and retrovirus vectors and targeting gene delivery for optimal efficiency of gene expression, 2. coupling the synthesis and release of the transgene insulin to serum glucose concentrations, especially with reference to the current promoters controlling at transcriptional level the ectopic insulin expression in autologous hepatocytes, 3. β-cell replacement strategies: engineering of β-cells, especially those derived from pluripotent stem cells, non β-cells, and on a new comer, the K cells. Recent advances in the use of stem cells for potential application in diabetes gene therapy are also discussed.
Keywords: diabetes gene therapy, diabetes mellitus, dm, ddm
Current Gene Therapy
Title: Diabetes Gene Therapy: Potential and Challenges
Volume: 3 Issue: 1
Author(s): Ruian Xu, Hua Li, Tse Lai-yin, Kung Hsiang-fu, Hongyan Lu and Karen S. L. Lam
Affiliation:
Keywords: diabetes gene therapy, diabetes mellitus, dm, ddm
Abstract: Gene therapy, developing rapidly as a result of advances in molecular biology and the Human Genome Project, is now highlighted as a most hopeful technology of the 21st century. The major goal of gene therapy in diabetes mellitus (DM) is to maintain euglycemia in face of wide variations in dietary intake. Although some obstacles remain to be overcome, the risk-benefit ratio of gene therapy in DM is better than that of lifelong injections of insulin, and islet transplantation, which faces the problems of donor shortage and rejection. This review focuses on the recent advances in gene therapy of insulin-requiring diabetes, with particular emphasis on 1. the gene delivery systems by viral vectors, since most gene therapy approaches for DM involve the use of viral vectors, paying special attention to current efforts to overcome the disadvantages of adenovirus, adenovirus-associated virus and retrovirus vectors and targeting gene delivery for optimal efficiency of gene expression, 2. coupling the synthesis and release of the transgene insulin to serum glucose concentrations, especially with reference to the current promoters controlling at transcriptional level the ectopic insulin expression in autologous hepatocytes, 3. β-cell replacement strategies: engineering of β-cells, especially those derived from pluripotent stem cells, non β-cells, and on a new comer, the K cells. Recent advances in the use of stem cells for potential application in diabetes gene therapy are also discussed.
Export Options
About this article
Cite this article as:
Xu Ruian, Li Hua, Lai-yin Tse, Hsiang-fu Kung, Lu Hongyan and Lam S. L. Karen, Diabetes Gene Therapy: Potential and Challenges, Current Gene Therapy 2003; 3 (1) . https://dx.doi.org/10.2174/1566523033347444
DOI https://dx.doi.org/10.2174/1566523033347444 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Melatonin Signaling in Health and Disease
Melatonin regulates a multitude of physiological functions, including circadian rhythms, acting as a scavenger of free radicals, an anti-inflammatory agent, a modulator of mitochondrial homeostasis, an antioxidant, and an enhancer of nitric oxide bioavailability. AANAT is the rate-limiting enzyme responsible for converting serotonin to NAS, which is further converted to ...read more
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers.
Programmed cell death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Evaluation of Thiol/Disulfide Homeostasis in Pediatric Patients with Diabetic Ketoacidosis
Combinatorial Chemistry & High Throughput Screening Targeting Heme Oxygenase-1 in Vascular Disease
Current Drug Targets Autophagy and Mitochondria in Obesity and Type 2 Diabetes
Current Diabetes Reviews Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology
Current Drug Targets Conjugative Post-Translational Modifications for Pharmacological Improvement of Therapeutic Proteins
Current Proteomics Radionuclide PET and PET/CT in Coronary Artery Disease
Current Pharmaceutical Design Coronary Calcium Risk Score and Cardiovascular Risk
Current Vascular Pharmacology Tankyrase as a Novel Molecular Target in Cancer and Fibrotic Diseases
Current Drug Targets Epigenomic-Basis of Preemptive Medicine for Neurodevelopmental Disorders
Current Genomics Involvement of Cysteine Proteases in Cancer
Current Medicinal Chemistry Recent Developments in the Design of Orally Bioavailable β3-Adrenergic Receptor Agonists
Current Medicinal Chemistry Effects of PPARγ Ligands on Vascular Tone
Current Molecular Pharmacology The Role of Atypical Antipsychotic Agents in the Treatment of Schizophrenia and Schizoaffective Disorders in the Elderly
Current Drug Safety Subject Index To Volume 4
Cardiovascular & Hematological Agents in Medicinal Chemistry Insulin Secretagogues, Sulfonylurea Receptors and KATP Channels
Current Pharmaceutical Design Endocarditis Due to Salmonella Enterica Subsp. Arizonae in a Patient with Sickle Cell Disease: A Case Report and Review of the Literature
Cardiovascular & Hematological Disorders-Drug Targets Nutritional Control, Gene Regulation, and Transformation of Vascular Smooth Muscle Cells in Atherosclerosis
Cardiovascular & Hematological Disorders-Drug Targets Cytochrome P450 and Steatosis
Current Drug Metabolism Anti-Diabetic Effects of Isolated Lipids from Natural Sources through Modulation of Angiogenesis
Current Molecular Pharmacology Obesity and Arterial Compliance Alterations
Current Vascular Pharmacology